ALIMTA? (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer , according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a phase II clinical trial at the University of Texas M. D. Anderson Cancer Center.
North Central Cancer Treatment Group researchers, based at Mayo Clinic in Rochester, Minn., have generated preliminary data suggesting that a form of American ginseng provides greater improvements in fatigue and vitality in patients who receive the highest doses tested, compared to lower doses or no treatment.
Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at the University of Texas M. D. Anderson Cancer Center.
Last year, a groundbreaking international project found that a group of Japanese patients with advanced non-small cell lung cancer survived longer ?and had a higher rate of side effects ? than U.S. patients with the same diagnosis,.when both groups were given two well-known drugs for the disease.
Women are much more interested in a man’s personality and looks than the size of his penis, but men can experience real anxiety even if they are average sized, according to a research review published in the June issue of the urology journal BJU International.
A University of Pittsburgh School of Medicine research team, collaborating with scientists from Stanford University, have developed a new, smaller gene therapy vector that may be effective in delivering a radioprotective enzyme systemically throughout the body which may spare healthy tissue the long-term consequences of therapeutic irradiation.
Oregon Health & Science University Cancer Institute researchers have identified a protein that is a strong indicator of survival for men with advanced prostate cancer.